SU2C CATALYST CLINICAL TRIAL

NCT02657889:  “Phase 1/2 trial of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer.”

PI:  Panagiotis A. Konstantinopoulos, MD, PhD – DFCI


NCT01623349:  “Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer”

This is a phase I trial to establish the MTD of the PARPi olaparib and the alpha-specific PI3K inhibitor BYL719 in patients with ovarian cancer and triple negative breast cancer.

PI:  Ursula Matulonis, MD – DFCI

NCT01434316: “Veliparib and Dinaciclib in Patients with Solid tumors”

Phase 1 trial of Dinaciclib and Veliparib with expansion cohorts in breast cancer and other solid tumors (ovarian).

PI:  Geoffrey I. Shapiro, MD, PhD – DFCI

NCT01891344:  “A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)”

Phase II biomarker study of Rucaparib in women with recurrent ovarian cancer.

PI:  Elizabeth Swisher, MD – UWASH